ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects (HVFE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02058784
Recruitment Status : Completed
First Posted : February 10, 2014
Last Update Posted : February 23, 2017
Sponsor:
Collaborator:
Celerion
Information provided by (Responsible Party):
Helsinn Healthcare SA

Brief Summary:
Open label study of Pracinostat will be tested to assess the effect of food on the single-dose pharmacokinetics in healthy non-smoking and smoking adult subjects under fasted and fed conditions.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Moderate to Heavy Smokers Non-smokers Drug: pracinostat Early Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A 2-Cohort Study to Evaluate the Effect of Food and the Effect of Cigarette Smoking on the Single-Dose Bioavailability of Pracinostat in Healthy Adult Subjects
Study Start Date : February 2014
Actual Primary Completion Date : March 2014
Actual Study Completion Date : March 2014

Arm Intervention/treatment
Experimental: Single-dose food effect in nonsmokers
Randomized, two-treatment design in nonsmoking healthy subjects. Single-dose pracinostat to be given under fasted and fed conditions followed by PK sampling for up to 48 hour post dose.
Drug: pracinostat
Experimental: Single-dose food effect in smokers
Single-dose parallel treatment design in moderate to heavy smoking healthy subjects. Single-dose pracinostat will be given under fasted conditions followed by PK blood sampling up to 48 hours.
Drug: pracinostat



Primary Outcome Measures :
  1. Assess the effect of food on a single-dose PK of pracinostat in nonsmoking healthy adult subjects [ Time Frame: 3 days ]
    Assess the ratios of least square means of pracinostat plasma PK parameters AUC 0-t, AUC 0-inf and Cmax for pracinostat under fed versus fasted conditions


Secondary Outcome Measures :
  1. Evaluate the safety and tolerability of a single-dose of pracinostat under fasted and fed conditions in healthy nonsmoking and smoking adult subjects [ Time Frame: 1 month ]
    All types of adverse events, physical exams, vital signs, 12-lead ECGs, and laboratory safety tests will be performed



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, adult, male or female, 18-55 years of age, inclusive, at screening.
  • Cohort 1 only: continuous nonsmoker who has not used nicotine-containing products for at least 6 months prior to the first dose and confirmed by urine cotinine test at screening.
  • Cohort 2 only: moderate to heavy smokers defined as > 1 pack of cigarettes per day or > 39 cigarettes per week for at least 6 months prior to the first dose and confirmed by urine cotinine test at screening.
  • Body Mass Index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.
  • Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI.
  • For a female of non-childbearing potential:
  • A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to study start. A male who has been vasectomized less than 4 months prior to study start must follow the same restrictions as a non vasectomized male).
  • Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol

Exclusion Criteria:

  • Subject is mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected during the conduct of the study.
  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI.
  • History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  • History or presence of alcoholism or drug abuse within the past 2 years prior to screening.
  • History or presence of hypersensitivity or idiosyncratic reaction to the study medication or related compounds.
  • History of prolonged QT syndrome.
  • Positive urine drug and alcohol results at screening or check-in.
  • Positive results at screening for HIV, HBsAg or HCV.
  • Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
  • Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
  • QTcF interval, is >430 msec (males) or >450 msec (females) or deemed clinically abnormal by the PI at screening or Period 1 check-in
  • Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning approximately 14 days prior to the first dose of study medication and throughout the study.
    • Any drugs known to be significant inducers of CYP enzymes, including St. John's Wort, for 28 days prior to the first dose dosing of study medication and throughout the study. Appropriate sources will be consulted by the PI or designee to confirm lack of PK/pharmacodynamics interaction with study medication.
  • Have been on a diet incompatible with the on-study diet, in the opinion of the PI, within the 28 days prior to the first dose of study medication(s), and throughout the study.
  • Hemoglobin, platelet count or absolute neutrophils below the lower limit of normal at screening.
  • Potassium or magnesium below the lower limit of normal at screening.
  • Aspartate aminotransferase and alanine aminotransferase above upper limit of normal at screening.
  • Donation of blood or significant blood loss within 56 days prior to the first dose of study medication.
  • Plasma donation within 7 days prior to the first dose of study medication.
  • Participation in another clinical trial within 28 days prior to the first dose of study medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02058784


Locations
United States, Arizona
Celerion
Tempe, Arizona, United States, 67296
Sponsors and Collaborators
Helsinn Healthcare SA
Celerion
Investigators
Principal Investigator: Terry E O'Reilly, MD Celerion

Responsible Party: Helsinn Healthcare SA
ClinicalTrials.gov Identifier: NCT02058784     History of Changes
Other Study ID Numbers: MEI-006
First Posted: February 10, 2014    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017